Lewisburg senior Jon Hess has an opportunity to achieve something that not even his two older Division I-level runner brothers did: win a medal at the PIAA state track and field meet. In fact, Hess ...

NOTES: Track and field bests are compiled from results sent to the Sun-Gazette. Only top 8 listed for each event for Class AA and Class AAA. Only one relay team per school listed. All area coaches ...

Brandy Jean Workman and Zachary Eli Zuback on April 24 ... Kelley for $185,000, property in Chapman Township. — Patricia L. Barner Estate and Executor Rodney L. Barner to David F.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

"Eli’s poster design captures the personality ... columnist for the Detroit Free Press, Genna Barner, page designer for The Detroit News; and Fox 2 Detroit news anchor and reporter Amy Lange.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...